Literature DB >> 23242672

Tumor microenvironment and myeloid-derived suppressor cells.

Viktor Umansky1, Alexandra Sevko.   

Abstract

Tumor progression has been demonstrated to be supported by chronic inflammatory conditions developed in the tumor microenvironment and characterized by the long-term secretion of various inflammatory soluble factors (including cytokines, chemokines, growth factors, reactive oxygen and nitrogen species, prostaglandins etc.) and strong leukocyte infiltration. Among leukocytes infiltrating tumors, myeloid-derived suppressor cells (MDSCs) represent one of the most important players mediating immunosuppression. These cells may not only strongly inhibit an anti-tumor immune reactions mediated by T cells but also directly stimulate tumorigenesis, tumor growth and metastasis by enhancing neoangiogenesis and creating a suitable environment for the metastatic formation. This review provides an overview of interactions between MDSCs and tumor cells leading to MDSC generation, activation and migration to the tumor site, where they can strongly enhance tumor progression. Better understanding of the MDSC-tumor interplay is critical for the development of new strategies of tumor immunotherapy.

Entities:  

Year:  2012        PMID: 23242672      PMCID: PMC3717060          DOI: 10.1007/s12307-012-0126-7

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  119 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 2.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

3.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors:  Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

Review 4.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 5.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

6.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Authors:  Alexander M Lesokhin; Tobias M Hohl; Shigehisa Kitano; Czrina Cortez; Daniel Hirschhorn-Cymerman; Francesca Avogadri; Gabrielle A Rizzuto; John J Lazarus; Eric G Pamer; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Res       Date:  2011-12-15       Impact factor: 12.701

7.  Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

Authors:  Renée Lengagne; Frédérique-Anne Le Gal; Marylène Garcette; Laurence Fiette; Patrick Ave; Masashi Kato; Jean-Paul Briand; Christian Massot; Izumi Nakashima; Laurent Rénia; Jean-Gérard Guillet; Armelle Prévost-Blondel
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

8.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

10.  Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression.

Authors:  Pampee P Young; Shidrokh Ardestani; Bin Li
Journal:  Cancer Microenviron       Date:  2010-04-20
View more
  49 in total

1.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

2.  Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.

Authors:  Jian-Qiang Lu; Benjamin Adam; Andrew S Jack; Anna Lam; Robert W Broad; Constance L Chik
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 3.  Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

Authors:  C Marcela Diaz-Montero; Jim Finke; Alberto J Montero
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

4.  CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

Authors:  Ming T Cheah; James Y Chen; Debashis Sahoo; Humberto Contreras-Trujillo; Anne K Volkmer; Ferenc A Scheeren; Jens-Peter Volkmer; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 5.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

6.  MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.

Authors:  Junfeng Wang; Fang Yu; Xuemei Jia; Stephen Iwanowycz; Yuzhen Wang; Shiang Huang; Walden Ai; Daping Fan
Journal:  Int J Cancer       Date:  2014-08-30       Impact factor: 7.396

Review 7.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

8.  [Role of CCL5/CCR5 in the perineural invasion of salivary adenoid cystic carcinoma cells].

Authors:  Li Tianyi; Shen Zhiyuan
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-10-01

9.  Evidence for interaction of the NLRP3 inflammasome and Bruton's tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta.

Authors:  Brooke Benner; Luke Scarberry; Andrew Stiff; Megan C Duggan; Logan Good; Gabriella Lapurga; Jonathan P Butchar; Susheela Tridandapani; William E Carson
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

Review 10.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.